Management of type 2 diabetes mellitus in older patients: Current and emerging treatment options

Diabetes Therapy

Volumn 4, Issue 2, 2013, Pages 239-256

  Moghissi, Etie ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Elderly; Emerging therapies; Hypoglycemia; Insulin; Management; Treatment guidelines; Type 2 diabetes

Indexed keywords

ALOGLIPTIN; ALOGLIPTIN PLUS METFORMIN; ALOGLIPTIN PLUS PIOGLITAZONE; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INSULIN; INSULIN DEGLUDEC; INSULIN GLARGINE; INSULIN PEGLISPRO; ISOPHANE INSULIN; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; METFORMIN PLUS SITAGLIPTIN; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

CARDIOVASCULAR DISEASE; COGNITION; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DIET; DISEASE DURATION; ECONOMIC ASPECT; EXERCISE; FALLING; GERIATRICS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; LIFE EXPECTANCY; META ANALYSIS (TOPIC); METABOLISM; MILD RENAL IMPAIRMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYPHARMACY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84899843245     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-013-0039-6     Document Type: Review

References (96)

1. Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care. 2012;35:2650-64.
2. Caspersen CJ, Thomas GD, Boseman LA, et al. Aging, diabetes, and the public health system in the United States. Am J Public Health. 2012;102: 1482-97.
3. Narayan KM, Boyle JP, Geiss LS, et al. Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care. 2006;29:2114-6.
4. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
5. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012;35(Suppl 1):S11-63.
6. Brown AF, Mangione CM, Saliba D, et al. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003;51: S265-80.
7. Spain M, Edlund BJ. Introducing insulin into diabetes management: transition strategies for older adults. J Gerontol Nurs. 2011;37:10-5.
8. Fu AZ, Qiu Y, Davies MJ, et al. Initial sulfonylurea use and subsequent insulin therapy in older subjects with type 2 diabetes mellitus. Diabetes Ther. 2012;3:12.
9. Chang AM, Halter JB. Aging and insulin secretion. Am J Physiol Endocrinol Metab. 2003;284:E7-12.
10. Neumiller JJ, Setter SM. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother. 2009;7:324-42.
11. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-59.
12. Ismail-Beigi F, Moghissi E, Tiktin M, et al. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011;154:554-9.
13. Kalyani RR, Saudek CD, Brancati FL, et al. Association of diabetes, comorbidities, and A1C with functional disability in older adults: results from the National Health and Nutrition Examination Survey (NHANES), 1999-2006. Diabetes Care. 2010;33:1055-60.
14. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-72.
15. Whitmer RA, Karter AJ, Yaffe K, et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301:1565-72.
16. Lipscombe LL, Austin PC, Manuel DG, et al. Income-related differences in mortality among people with diabetes mellitus. CMAJ. 2010;182:E1-17.
17. Bramlage P, Gitt AK, Binz C, et al. Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia. Cardiovasc Diabetol. 2012;11:122.
18. Johnston SS, Conner C, Aagren M, et al. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2011;34:1164-70.
19. Johnston SS, Conner C, Aagren M, et al. Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes. Diabetes Obes Metab. 2012;14:634-43.
20. Laiteerapong N, Karter AJ, Liu JY, et al. Correlates of quality of life in older adults with diabetes: the diabetes & aging study. Diabetes Care. 2011;34: 1749-53.
21. Abbatecola AM, Maggi S, Paolisso G. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. Drugs Aging. 2008;25:913-25.
22. Punthakee Z, Miller ME, Launer LJ, et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care. 2012;35:787-93.
23. Minaker KL, Rowe JW, Tonino R, et al. Influence of age on clearance of insulin in man. Diabetes. 1982;31:851-5.
24. Reaven GM, Greenfield MS, Mondon CE, et al. Does insulin removal rate from plasma decline with age? Diabetes. 1982;31:670-3.
25. Chelliah A, Burge MR. Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging. 2004;21:511-30.
26. Pratley RE, Gilbert M. Clinical management of elderly patients with type 2 diabetes mellitus. Postgrad Med. 2012;124:133-43.
27. VA/DoD clinical practice guideline for the management of diabetes mellitus. Version 4.0. Washington, DC: Veterans Health Administration and Department of Defense; 2010.
28. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care. 2013;36(Suppl 1):S11-66.
29. Lee SJ, Boscardin WJ, Stijacic CI, et al. The risks and benefits of implementing glycemic control guidelines in frail older adults with diabetes mellitus. J Am Geriatr Soc. 2011;59:666-72.
30. Sinclair A, Morley JE, Rodriguez-Manas L, et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc. 2012;13:497-502.
31. Ross SA, Ekoe JM. Incretin agents in type 2 diabetes. Can Fam Physician. 2010;56:639-48.
32. Raccah D, Miossec P, Esposito V, et al. Efficacy and safety of lixisenatide in elderly ([65 yr) and very elderly ([/=75 yr) patients with type 2 diabetes: an analysis from the GetGoal Phase 3 Program [abstract 972-P]. Diabetes. 2012;61:A248.
33. Umpierrez GE, Meneghini L. Reshaping diabetes care: the fundamental role of DPP-4 inhibitors and GLP-1 receptor agonists in clinical practice. Endocr Pract. 2013; [Epub ahead of print]. doi:10.4158/ EP12292.RA.
34. Russell S. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. Int J Clin Pharm. 2013;35:159-72.
35. Bourdel-Marchasson I, Schweizer A, Dejager S. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hosp Pract (Minneap). 2011;39:7-21.
36. Mathieu C, Bollaerts K. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. Int J Clin Pract. 2007;61:29-37.
37. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2011.
38. Victoza [package insert]. Princeton, NJ: Novo Nordisk A/S; 2012.
39. Bydureon [package insert]. San Diego, CA: Amylin Pharmaceuticals; 2012.
40. Pencek R, Blickensderfer A, Li Y, et al. Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgrad Med. 2012;124:21-32.
41. Bode BW, Brett J, Falahati A, et al. Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes [/=65 and \65 years of age: a pooled analysis from phase III studies. Am J Geriatr Pharmacother. 2011;9:423-33.
42. Lowes R. Once-weekly exenatide okayed by FDA for T2DM after long look. 2012. http://www.medscape.com/viewarticle/757664. Accessed 28 Jan 2013.
43. Januvia [package insert]. Whitehouse Station, NJ: Merck & CO., Inc.; 2012.
44. Onglyza [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2011.
45. Tradjenta [package insert]. Ridgefield, CT: Boehringer Ingelheim International GmbH; 2012.
46. Tucker M. FDA licenses diabetes drug alogliptin, in 3 formulations. 2013. http://wwwmedscape.com/viewarticle/778235_print. Accessed 28 Jan 2013.
47. Shankar R, Engel S, Xu L, et al. Sitagliptin provides similar glycemic improvement with less hypoglycemia in the elderly with type 2 diabetes mellitus compared to sulfonylurea. Diabetes. 2012;61:A278.
48. Charbonnel B, Barnett A, Monyak J, et al. Efficacy and safety of saxagliptin in combination with insulin in elderly patients with type 2 diabetes [abstract 1048-P]. Diabetes. 2012;61:A269.
49. Barnett A, Huisman H, Jones R, et al. Efficacy and safety of Linagliptin in elderly patients ([/=70 Years) with type 2 diabetes [abstract 1017-P]. Diabetes. 2012;61:A260-1.
50. Iqbal N, Allen E, Donavan M, Ohman P. Long-term safety and tolerability of saxagliptin add-on therapy in elderly patients with type 2 diabetes [abstract 1160-P]. Diabetes. 2012;61:A299.
51. Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27:1049-58.
52. Janumet XR (sitagliptin and metformin HCl extended-release) tablets [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2012.
53. St Onge EL, Miller S, Clements E. Sitagliptin/ metformin (Janumet) as combination therapy in the treatment of type-2 diabetes mellitus. Pharm Ther. 2012;37:699-708.
54. Pratley RE, McCall T, Fleck PR, et al. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc. 2009;57:2011-9.
55. Clinicaltrials.gov. Study of Sitagliptin in Older Type 2 Diabetics (Clincal trial identifier NCT00305604), 2013. http://clinicaltrials.gov/show/NCT00305604. Accessed 2 Jan 2013.
56. Clinicaltrials.gov. Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin (GENERATION) (Clincal trial identifier NCT01006603), 2013. http://clinicaltrials.gov/show/NCT01006603. Accessed 26 Jan 2013.
57. Clinicaltrials.gov. Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes (Clinical trial identifier: NCT01084005), 2013. http://clinicaltrials.gov/ct2/show/NCT01084005. Accessed 26 Jan 2013.
58. Clinicaltrials.gov. Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics (Clinical trials identifier: NCT00707993), 2013. http://clinicaltrials.gov/ct2/show/NCT00707993. Accessed 27 Jan 2013.
59. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194-206.
60. Arold G, Kupcova V, Thrane M, et al. Insulin degludec has similar pharmacokinetic properties in subjects with hepatic impairment when compared to subjects with normal hepatic function [abstract 1119-P]. Diabetes. 2012;61:A289.
61. European Medicines Agency. Annex 1,2,3 Summary of Product Characteristics Galvus 50 mg tablets. 2012. http://www.ema.europaeu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000771/WC500020327.pdf. Accessed 26 Jan 2013.
62. Kiss I, Arold G, Bottcher G, et al. Insulin degludec has similar pharmacokinetic properties in subjects with renal impairment and subjects with normal renal function [abstract 1151-P]. Diabetes. 2012;61:A296-7.
63. Linnebjerg H, Choi S, Lam ECQ, et al. Pharmacokinetics (PK) of the novel, long-acting basal insulin LY2605541 in subjects with varying degrees of renal function [abstract 1148-P]. Diabetes. 2012;61:A296.
64. Babu A. Canagliflozin for the treatment of type 2 diabetes. Drugs Today (Barc). 2013;49:363-76.
65. Demaris KM, White JR. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc). 2013;49:289-301.
66. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8:495-502.
67. Nainggolan L. FDA Approves Canagliflozin, a First-in-Class Diabetes Drug. 2013. http://www.medscape.com/viewarticle/781709. Accessed 1 Aug 2013.
68. Bailey CJ, Gross JL, Hennicken D, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43.
69. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013; [Epub ahead of print].
70. Bode B, Stenlof K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995). 2013;41:72-84.
71. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
72. Li C, Ford ES, Zhao G, et al. Trends of insulin use among US adults with type 2 diabetes: the behavioral risk factor surveillance system, 1995-2007. J Diabetes Complicat. 2012;26:17-22.
73. Tanwani LK. Insulin therapy in the elderly patient with diabetes. Am J Geriatr Pharmacother. 2011;9:24-36.
74. Zafon C, Creus C. A comparison on insulin regimen treatment of elderly ([70 years) and younger (\70 years) type 2 diabetic patients in actual clinical practice. Acta Diabetol. 2013;50:33-7.
75. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540-59
76. Lee P, Chang A, Blaum C, et al. Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis. J Am Geriatr Soc. 2012;60:51-9.
77. Garber AJ, Clauson P, Pedersen CB, et al. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials. J Am Geriatr Soc. 2007;55:1735-40.
78. Heise T, Nosek L, Bottcher SG, et al. Ultra-long- acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14:944-50.
79. Pandyarajan V, Weiss MA. Design of non-standard insulin analogs for the treatment of diabetes mellitus. Curr Diab Rep. 2012;12:697-704.
80. Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29:2104-14.
81. Sinha VP, Howey DC, Soon DK, et al. Single-dose pharmacokinetics (PK) and glucodynamics (GD) of the novel, long-acting basal insulin LY2605541 in healthy subjects [abstract 1063-P]. Diabetes. 2012;61:A273.
82. Garber AJ, King AB, Del PS, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to- target non-inferiority trial. Lancet. 2012;379:1498-507.
83. Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35:2464-71.
84. Ratner RE, Gough SCL, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175-84.
85. Gough S, Ratner R, Mathieu C, Del Prato S, Bode B, Mersebach H, et al. Prospectively planned meta- analysis comparing hypoglycaemia rates of insulin degludec with those of insulin glargine in all patients and an elderly ([65 year) subgroup [poster]. European Association for the Study of Diabetes: October 1, 2012; Berlin, Germany.
86. Bergenstal RM, Rosenstock J, Arakaki RF, et al. A randomized, controlled study of once daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care. 2012;35:2140-7.
87. The DCCT Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am J Med. 1991;90:450-9.
88. Fidler C, Elmelund CT, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ. 2011;14:646-55.
89. Wild D, von Maltzahn R, Brohan E, et al. A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education. Patient Educ Couns. 2007;68:10-5.
90. Nguyen HT, Arcury TA, Grzywacz JG, et al. The association of mental conditions with blood glucose levels in older adults with diabetes. Aging Ment Health. 2012;16:950-7.
91. Tasci I, Naharci MI, Bozoglu E, et al. Cognitive and functional influences of vildagliptin, A DPP-4 inhibitor, added to ongoing metformin therapy in elderly with type 2 diabetes. Endocr Metab Immune Disord Drug Targets 2013; [Epub ahead of print].
92. Nandipati S, Luo X, Schimming C, et al. Cognition in non-demented diabetic older adults. Curr Aging Sci. 2012;5:131-5.
93. Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes. 2003;111:405-14.
94. Bodmer M, Meier C, Krahenbuhl S, et al. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care. 2008;31:2086-91.
95. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106-18.
96. Hirshberg B, Raz I. Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. Diabetes Care. 2011;34:S101-6.